Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
26 hedge funds and large institutions have $3.67M invested in Oncternal Therapeutics, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
8% more funds holding
Funds holding: 24 → 26 (+2)
9% less capital invested
Capital invested by funds: $4.05M → $3.67M (-$379K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PPW
Pasadena Private Wealth
Pasadena,
California
|
+$215K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$43.2K |
| 3 |
Morgan Stanley
New York
|
+$36.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.5K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$22.2K |
| 2 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
-$7.79K |
| 3 |
Millennium Management
New York
|
-$1.37K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.18K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.03K |
ONCT Hedge Fund Activity: Q2 2024 in Review
26 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2024, worth a combined $3.67M — down 9.4% from $4.05M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ONCT positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Pasadena Private Wealth, opening a new position worth an estimated $215K. The largest seller was ADAR1 Capital Management, exiting entirely with an estimated $22.2K sold.
- 26 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2024, up from 24 in Q1 2024.
- Funds reported $3.67M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2024, down 9.4% quarter-over-quarter.
- 4 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2024 and 2 closed out, a net change of +2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2024 was Pasadena Private Wealth, an estimated $215K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2024 was ADAR1 Capital Management, an estimated $22.2K sold.
Based on aggregated 13F filings for Q2 2024.